TriangleStudy reference · NCT01844505
CheckMate 067
Nivolumab with or without ipilimumab: ten-year outcomes
Fixed release · explorer-2026-09-11At ten years, estimated overall survival was 43% with nivolumab plus ipilimumab, 37% with nivolumab, and 19% with ipilimumab.
Estimated survival at 10 years
Overall survival · percentage alive in each trial group
The small black line shows uncertainty (95% confidence interval), where available. These estimates describe study groups, not an individual’s chance of survival.
Overall-survival HR versus ipilimumab: 0.53 (95% CI 0.44–0.65) for the combination; 0.63 (0.52–0.76) for nivolumab.
Grade 3–4 treatment-related adverse events
Separate 2017 report; cutoff May 24, 2017; minimum follow-up 36 months. Lower percentages mean fewer reported severe events.
313 combination; 313 nivolumab; 311 ipilimumab participants in the safety analysis.
Put the research in context
Who was studied?
Compare the reported population with what you know. It is fine to be unsure—those are useful questions for your care team.
Read the original sources →These are reported population details, not a complete list of eligibility criteria. Who could enroll, who participated, and whose results were analyzed can differ. This checklist does not score your match, recommend treatment, or determine trial eligibility.
Your selections and question stay on this page only. They are not saved or sent to Triangle. Copy your note before leaving; refreshing clears it.
Keep your next appointment in mind.
Copy your question, then sign in to Triangle.
This note is not transferred automatically.
Study design & endpoints
Double-blind, randomized phase 3 trial; 945 participants in three groups.
Co-primary endpoints: overall survival and progression-free survival, each nivolumab group versus ipilimumab.
What the chart cannot tell you
- The trial was not designed or powered to compare the combination directly with nivolumab alone. That comparison is descriptive.
- Final confidence intervals were not adjusted for multiple comparisons.
- The harms displayed here are from the earlier 2017 report, not ten-year cumulative rates.
Results are group estimates, not a personalized forecast, treatment recommendation, or confirmation of trial eligibility.
Full results table
| Group | Efficacy n | Median overall survival, months (CI) | Survival at 10 years (95% CI) | Severe events |
|---|---|---|---|---|
| Nivolumab + ipilimumab | 314 | 71.9 (38.2–114.4) | 43% (38–49%) | 59% |
| Nivolumab | 316 | 36.9 (28.2–58.7) | 37% (32–43%) | 21% |
| Ipilimumab | 315 | 19.9 (16.8–24.6) | 19% (15–24%) | 28% |
Grade 3–4 treatment-related adverse events. 313 combination; 313 nivolumab; 311 ipilimumab participants in the safety analysis.
Median survival is a time point, not average lifespan. Confidence levels and analysis details are reported with the source.